PATENT CLAIM ANALYSIS

Application Number: 15877103
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["548", "100000"]

Abstract:
The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.

Claim (Index 17):
The method according to  claim 15 , further including the steps of\n a) irradiating the tumour cells; or b) administering one or more chemotherapeutic agents and/or therapies to the subject; before, during or after the administration of the compounds of formula (I).

Metadata:
- Claim Count in Document: 2.0
- Percentile: 86.0
- Lexical Diversity: 1.51351
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15339041', '14423359', '10577078', '10529772', '15378360']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8043204591696796
- 35 USC 102 Novelty (BERT): 0.7417227736630558
- Combined Prediction Score: 0.7980606906190173
- Mean Citation Score: 515.65723
- Max Citation Score: 920.28534
- Similarity Product: 822.1088832018436

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test